Skip to main content

Mechanisms · Mechanism of Action

Noribogaine: The Long-Tail Metabolite

Noribogaine is ibogaine's CYP2D6-formed metabolite: cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.

DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team

Quick Answer

What is noribogaine: the long-tail metabolite in ibogaine pharmacology?

Noribogaine (12-hydroxyibogamine) is the primary active metabolite of ibogaine, formed in vivo by hepatic CYP2D6 O-demethylation. It has a substantially longer plasma half-life than parent ibogaine, a cleaner mu-opioid partial-agonist profile, and a smaller hERG/QT signal, which is why some research programs have explored noribogaine alone as a development candidate. At MindScape, noribogaine is the molecule responsible for most of the post-flood-dose clinical tail and is the reason continuous cardiac telemetry extends 72-96 hours after dosing.

Reviewed by Dr. Arellano, M.D. (May 2026)

Formation and disposition

Noribogaine is formed by CYP2D6-mediated O-demethylation of ibogaine, primarily in the liver. The conversion rate depends heavily on CYP2D6 metabolizer status (see the Pharmacokinetics deep-dive).

Once formed, noribogaine is highly lipophilic and accumulates in adipose tissue. Plasma elimination half-life estimates range from 28 to 49 hours, substantially longer than parent ibogaine.

Receptor profile differences from parent ibogaine

Compared to ibogaine, noribogaine has a cleaner pharmacological signature: stronger mu-opioid partial-agonist activity, kappa-opioid partial-agonist activity, serotonin transporter inhibition, and a notably smaller hERG/QT signal in cardiac assays.

These differences are why noribogaine has been explored as a stand-alone development candidate (Glue et al. 2015, 2016). It preserves the long-tail anti-craving and mood-elevating effects while reducing the acute QT-prolongation risk that comes with parent ibogaine.

  • Mu-opioid receptor: partial agonist (cleaner than parent ibogaine).
  • Kappa-opioid receptor: partial agonist activity.
  • Serotonin transporter (SERT): inhibition; contributes to mood-elevating tail.
  • hERG channel: substantially smaller QT-prolongation signal.

Why telemetry extends 72-96 hours

Although parent ibogaine clears within 24-36 hours of the flood dose, noribogaine concentrations remain pharmacologically active for days. The MindScape cardiac telemetry window is calibrated to this metabolite tail, not to parent ibogaine elimination.

This is also why patients can describe sustained mood and anti-craving effects in the week after the flood dose: the noribogaine tail is doing the work.

Targets

  • Mu-opioid receptor (partial agonist)
  • Kappa-opioid receptor
  • Serotonin transporter (SERT)
  • hERG channel (low signal)
  • CYP2D6 substrate

Citations & Reading

  • Glue P, et al. (2015). Drug Metabolism and Disposition, 43(1), 119-125.
  • Glue P, et al. (2016). Clinical Pharmacology in Drug Development, 5(6), 460-468.
  • Mash DC, et al. (2018). Frontiers in Pharmacology, 9, 529.
  • Maillet EL, et al. (2015). Neuropharmacology, 99, 675-688.

For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.

Related mechanisms

Clinical Calls

Have a question about this mechanism?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation